Sale

Cancer Cachexia Market

Global Cancer Cachexia Market Share, Size, Analysis, Forecast: By Therapeutics: Progestogens, Corticosteroids, Combination Therapies, Cannabinoids, Nonsteroidal anti-inflammatory drugs, Anabolic agents, Immunomodulatory agents, Others; By Mechanism of Action; By Distribution Channel; Regional Analysis; Supplier Landscape; 2024-2032

Global Cancer Cachexia Market Outlook

The global cancer cachexia market size attained a value of USD 2.32 billion in 2023 driven by continuous clinical trials in oncology, expanding mindfulness among individuals and healthcare experts, presence of an enormous pool of undiscovered patients, quick urbanisation, and expanding government support for healthcare. The market is anticipated to grow at a CAGR of 4.7% during the forecast period of 2024-2032 to attain a value of USD 3.51 billion by 2032.

 

Global Cancer Cachexia Market

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Global Cancer Cachexia Market Likely to be Driven by Rising Number of Cachexia Cases and Advancements in Treatment Systems

The global market for cancer cachexia is expected to be driven by rising instances of cachexia and developments in modern treatment systems. North America, Europe and Japan are expected to be key markets. Cases of cachexia are growing and presently, the condition affects nearly 1 percent of all patients. Recent years have witnessed increased understanding of the multifarious nature of cachexia, in particular, the function of inflammatory mediators and anabolic and catabolic imbalances. While many treatment methodologies have not been able to clear phase III clinical trials despite initial promise, the ghrelin receptor agonist anamorelin has delivered initial results.

Cachexia is a serious outcome of a variety of chronic conditions, and associated with a poor quality of life. In last-stage chronic heart failure, the occurrence of cachexia ranges from 5–15 percent; in cases of advanced cancer, the incidence of cachexia lies between 50–80 percent. Many people with chronic renal disease, chronic obstructive pulmonary disease (COPD), and rheumatoid arthritis develop cachexia as they near the end of their lives. Cachectic syndrome is a key source of morbidity and mortality in cancer patients. Cancer cachexia has also been linked to decreased chemotherapeutic efficacy, increased adverse effects, and discontinuation of treatment. Progressive cachexia signals poor prognosis with a shorter survival time, and explains close to 20 percent of all cancer deaths. If there is weight loss of 10 percent or more within a period of 6 months, it may indicate presence of cachexia. There is a direct relation between survival of cancer patients and rate and amount of weight loss.

Cachectic syndrome is described to have three stages - precachexia, cachexia, and refractory cachexia. In the precachectic stage, indications such as such as weight loss (less than 5 percent), anorexia, and impaired glucose tolerance appear. Advancement to cachexia depends on several factors including systemic inflammation, type and stage of cancer, low food intake, and response to treatment. In refractory cachexia, active weight loss management is rendered almost impossible due to active catabolism or presence of cachectic factors. Patients experiencing acute muscle wasting are not likely to gain from treatments aimed at achieving   lean tissue and function. In this phase, therapy seeks to mitigate symptoms and reduce distress rather than prolong life.

 

Combination Therapies Involving Novel Medicinal Agents Show Promise; New Drugs Expected to Stimulate Market

At present, cancer cachexia is incurable. Current therapies for cachexia entail a multidisciplinary approach; combination therapy including diet adjustments and exercise (where possible) has been integrated with new medicinal agents such as Megestrol acetate, medroxyprogesterone, ghrelin, and omega-3-fatty acid, among others. These treatments have been reported to yield better survival rates and quality of life. Advancements in treatment systems and promise shown by under-trial drugs are expected to boost the market.

In 2021, Helsinn, a Swiss pharmaceutical group engaged in the production of high-quality cancer care and rare disease products, announced the first launch of Adlumizo (anamorelin) to treat cancer cachexia in malignant non-small cell lung cancer, gastric cancer, pancreatic cancer and colorectal cancer in Japan, through Ono Pharmaceutical, its partner firm. Adlumizo (anamorelin), approved by the Japanese Health Authorities, has been shown to be effective in increasing body weight, muscle mass, and appetite in cancer cachexia patients.

AV-380 by AVEO is first-in-class, potent, humanized inhibitory IgG1 antibody targeting growth differentiation factor 15 (GDF15). Preclinical data suggest that inhibition of GDF15 leads to a switch from catabolism to anabolism, which indicates that GDF15 inhibition with AV-380 may reverse the effects of cachexia. As of 2023, AVEO Oncology completed enrolment in its phase I trial in Cachexia (In volunteers) in USA (Parenteral) (NCT04815551), and planned to commence a phase Ib trial in Cancer in mid-2022.

 

Global Cancer Cachexia Market Segmentation

 

Global Cancer Cachexia Market by Segment

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

By therapeutics, the market is divided into:

  • Progestogens
  • Corticosteroids
  • Combination Therapy
  • Others

By mechanism of action, the market is classified into:

  • Appetite Stimulators
  • Weight Loss Stabilizers

By distribution channel, the market is segmented into:

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

By region, the market is classified into:

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa

 

Global Cancer Cachexia Market by Region

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Key Industry Players in the Global Cancer Cachexia Market

The report presents a detailed analysis of the following key players in the market, looking into their capacity, and latest developments like capacity expansions, plant turnarounds, and mergers and acquisitions:

  • Merck & Co., Inc.
  • Aphios Corporation
  • Helsinn Healthcare SA
  • AVEO Pharmaceuticals, Inc.
  • Ono Pharmaceutical Co., Ltd.
  • Pfizer Inc.
  • Others

The EMR report gives an in-depth insight into the industry by providing a SWOT analysis as well as an analysis of Porter’s Five Forces model.

 

Key Highlights of the Report

REPORT FEATURES DETAILS
Base Year 2023
Historical Period 2017-2023
Forecast Period 2024-2032
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Therapeutics
  • Mechanism of Action
  • Distribution Channel
  • Region
Breakup by Therapeutics
  • Progestogens
  • Corticosteroids
  • Combination Therapies
  • Cannabinoids
  • Nonsteroidal anti-inflammatory drugs
  • Anabolic agents
  • Immunomodulatory agents
  • Ghrelin receptor agonists
  • Others
Breakup by Mechanism of Action
  • Appetite Stimulators
  • Weight Loss Stabilizers
Breakup by Distribution Channel
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Others
Breakup by Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa
Market Dynamics
  • Market Drivers and Constraints
  • SWOT Analysis
  • Porter’s Five Forces Model 
  • Key Demand Indicators
  • Key Price Indicators
  • Industry Events, Initiatives, and Trends 
  • Value Chain Analysis
Supplier Landscape
  • Market Structure
  • Company Profiles
    • Financial Analysis
    • Product Portfolio
    • Demographic Reach and Achievements
    • Mergers and Acquisitions
    • Certifications
Companies Covered
  • Aeterna Zentaris Inc.
  • Aphios Corporation
  • Atara Biotherapeutics Inc.
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • GTx, Inc.
  • Helsinn Group
  • Merck & Co., Inc.
  • Novartis AG
  • Ono Pharmaceutical Co., Ltd.
  • Pfizer Inc.
  • XBiotech Inc.

 

*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.

1    Preface
    1.1    Objectives of the Study
    1.2    Key Assumptions
    1.3    Report Coverage – Key Segmentation and Scope 
    1.4    Research Methodology
2    Executive Summary
3    Cancer Cachexia Disease Overview 

    3.1    Guidelines and Stages
    3.2    Pathophysiology
    3.3    Screening and Diagnosis
    3.4    Treatment Pathway 
4    Patient Profile
    4.1    Patient Profile Overview
    4.2    Patient Psychology and Emotional Impact Factors
    4.3    Risk Assessment and Treatment Success Rate
5    Cancer Cachexia Epidemiology Analysis
    5.1    Epidemiology Overview (2016-2031)
    5.2    North America Cancer Cachexia Epidemiology (2016-2031)
    5.3    Europe Cancer Cachexia Epidemiology (2016-2031)
    5.4    Asia-Pacific Cancer Cachexia Epidemiology (2016-2031)
    5.5    Latin America Cancer Cachexia Epidemiology (2016-2031)
    5.6    Middle East & Africa Cancer Cachexia Epidemiology (2016-2031)
6    Global Cancer Cachexia Market Overview 
    6.1    Global Cancer Cachexia Market Historical Value (2017-2023)
    6.2    Global Cancer Cachexia Market Forecast Value (2024-2032)
7    Global Cancer Cachexia Market Landscape
    7.1    Global Cancer Cachexia Market: Developers Landscape
        7.1.1    Analysis by Year of Establishment
        7.1.2    Analysis by Company Size
        7.1.3    Analysis by Region
    7.2    Global Cancer Cachexia Market: Product Landscape
        7.2.1    Analysis by Therapeutics
        7.2.2    Analysis by Mode of Action
        7.2.3    Analysis by Distribution Channel
8    Cancer Cachexia Challenges and Unmet Needs
    8.1    Treatment Pathway Challenges
    8.2    Compliance and Drop-Out Analysis
    8.3    Awareness and Prevention Gaps
9    Cost of Treatment
10    Global Cancer Cachexia Market Dynamics

    10.1    Market Drivers and Constraints
    10.2    SWOT Analysis
    10.3    Porter’s Five Forces Model
    10.4    Key Demand Indicators 
    10.5    Key Price Indicators
    10.6    Industry Events, Initiatives, and Trends  
    10.7    Value Chain Analysis
11    Global Cancer Cachexia Market Segmentation
    11.1    Global Cancer Cachexia Market by Therapeutics
        11.1.1    Market Overview
        11.1.2    Progestogens
        11.1.3    Corticosteroids
        11.1.4    Combination Therapies
        11.1.5    Cannabinoids
        11.1.6    Nonsteroidal anti-inflammatory drugs
        11.1.7    Anabolic agents
        11.1.8    Immunomodulatory agents
        11.1.9    Ghrelin receptor agonists
        11.1.10    Others
    11.2    Global Cancer Cachexia Market by Mechanism of Action
        11.2.1    Market Overview
        11.2.2    Appetite Stimulators
        11.2.3    Weight Loss Stabilizers
    11.3    Global Cancer Cachexia Market by Distribution Channel
        11.3.1    Market Overview
        11.3.2    Hospital Pharmacy
        11.3.3    Retail Pharmacy
        11.3.4    Online Pharmacy
        11.3.5    Others
    11.4    Global Cancer Cachexia Market by Region
        11.4.1    Market Overview
        11.4.2    North America
        11.4.3    Europe 
        11.4.4    Asia Pacific
        11.4.5    Latin America
        11.4.6    Middle East and Africa
12    North America Cancer Cachexia Market
    12.1    Market Share by Country
    12.2    United States of America
    12.3    Canada
13    Europe Cancer Cachexia Market
    13.1    Market Share by Country
    13.2    United Kingdom
    13.3    Germany
    13.4    France
    13.5    Italy
    13.6    Others
14    Asia Pacific Cancer Cachexia Market
    14.1    Market Share by Country
    14.2    China
    14.3    Japan
    14.4    India
    14.5    ASEAN
    14.6    Australia
    14.7    Others
15    Latin America Cancer Cachexia Market
    15.1    Market Share by Country
    15.2    Brazil
    15.3    Argentina
    15.4    Mexico
    15.5    Others
16    Middle East and Africa Cancer Cachexia Market
    16.1    Market Share by Country
    16.2    Saudi Arabia
    16.3    United Arab Emirates
    16.4    Nigeria
    16.5    South Africa
    16.6    Others
17    Regulatory Framework
    17.1    Regulatory Overview
        17.1.1    US FDA
        17.1.2    EU EMA
        17.1.3    INDIA CDSCO
        17.1.4    JAPAN PMDA
        17.1.5    Others
18    Patent Analysis
    18.1    Analysis by Type of Patent
    18.2    Analysis by Publication year
    18.3    Analysis by Issuing Authority
    18.4    Analysis by Patent Age
    18.5    Analysis by CPC Analysis
    18.6    Analysis by Patent Valuation 
    18.7    Analysis by Key Players
19    Grants Analysis
    19.1    Analysis by year
    19.2    Analysis by Amount Awarded
    19.3    Analysis by Issuing Authority
    19.4    Analysis by Grant Application
    19.5    Analysis by Funding Institute
    19.6    Analysis by NIH Departments
    19.7    Analysis by Recipient Organization 
20    Clinical Trials Analysis
    20.1     Analysis by Trial Registration Year
    20.2    Analysis by Trial Status
    20.3    Analysis by Trial Phase
    20.4    Analysis by Therapeutic Area
    20.5    Analysis by Geography
21    Funding and Investment Analysis
    21.1    Analysis by Funding Instances
    21.2    Analysis by Type of Funding
    21.3    Analysis by Funding Amount
    21.4    Analysis by Leading Players
    21.5    Analysis by Leading Investors
    21.6    Analysis by Geography
22    Partnership and Collaborations Analysis
    22.1    Analysis by Partnership Instances
    22.2    Analysis by Type of Partnership
    22.3    Analysis by Leading Players
    22.4    Analysis by Geography
23    Supplier Landscape
    23.1    Aeterna Zentaris Inc.
        23.1.1    Financial Analysis
        23.1.2    Product Portfolio
        23.1.3    Demographic Reach and Achievements
        23.1.4    Mergers and Acquisitions
        23.1.5    Certifications
    23.2    Aphios Corporation
        23.2.1    Financial Analysis
        23.2.2    Product Portfolio
        23.2.3    Demographic Reach and Achievements
        23.2.4    Mergers and Acquisitions
        23.2.5    Certifications
    23.3    Atara Biotherapeutics Inc.
        23.3.1    Financial Analysis
        23.3.2    Product Portfolio
        23.3.3    Demographic Reach and Achievements
        23.3.4    Mergers and Acquisitions
        23.3.5    Certifications
    23.4    Bristol-Myers Squibb Company
        23.4.1    Financial Analysis
        23.4.2    Product Portfolio
        23.4.3    Demographic Reach and Achievements
        23.4.4    Mergers and Acquisitions
        23.4.5    Certifications
    23.5    Eli Lilly and Company
        23.5.1    Financial Analysis
        23.5.2    Product Portfolio
        23.5.3    Demographic Reach and Achievements
        23.5.4    Mergers and Acquisitions
        23.5.5    Certifications
    23.6    GTx, Inc.
        23.6.1    Financial Analysis
        23.6.2    Product Portfolio
        23.6.3    Demographic Reach and Achievements
        23.6.4    Mergers and Acquisitions
        23.6.5    Certifications
    23.7    Helsinn Group
        23.7.1    Financial Analysis
        23.7.2    Product Portfolio
        23.7.3    Demographic Reach and Achievements
        23.7.4    Mergers and Acquisitions
        23.7.5    Certifications
    23.8    Merck & Co., Inc.
        23.8.1    Financial Analysis
        23.8.2    Product Portfolio
        23.8.3    Demographic Reach and Achievements
        23.8.4    Mergers and Acquisitions
        23.8.5    Certifications
    23.9    Novartis AG
        23.9.1    Financial Analysis
        23.9.2    Product Portfolio
        23.9.3    Demographic Reach and Achievements
        23.9.4    Mergers and Acquisitions
        23.9.5    Certifications
    23.10    Ono Pharmaceutical Co., Ltd.
        23.10.1    Financial Analysis
        23.10.2    Product Portfolio
        23.10.3    Demographic Reach and Achievements
        23.10.4    Mergers and Acquisitions
        23.10.5    Certifications
    23.11    Pfizer Inc.
        23.11.1    Financial Analysis
        23.11.2    Product Portfolio
        23.11.3    Demographic Reach and Achievements
        23.11.4    Mergers and Acquisitions
        23.11.5    Certifications
    23.12    XBiotech Inc.
        23.12.1    Financial Analysis
        23.12.2    Product Portfolio
        23.12.3    Demographic Reach and Achievements
        23.12.4    Mergers and Acquisitions
        23.12.5    Certifications
24    Cancer Cachexia Market- Distribution Model (Additional Insight)
    24.1    Overview 
    24.2    Potential Distributors 
    24.3    Key Parameters for Distribution Partner Assessment 
25    Key Opinion Leaders (KOL) Insights (Additional Insight)
26    Company Competitiveness Analysis (Additional Insight)

    26.1    Very Small Companies
    26.2    Small Companies
    26.3    Mid-Sized Companies
    26.4    Large Companies
    26.5    Very Large Companies
27    Payment Methods (Additional Insight)
    27.1    Government Funded
    27.2    Private Insurance
    27.3    Out-of-Pocket

 

*Additional insights provided are customisable as per client requirements.

Key Questions Answered in the Report

In 2023, the global market of Cancer Cachexia attained a value of USD 2.32 billion.

The market is anticipated to grow at a CAGR of 4.7% during the forecast period of 2024-2032 to reach a value of USD 3.51 billion by 2032.

The major drivers of the market include the neglected requirement for the therapy of cancer cachexia in creating economies, continuous clinical trials in oncology, expanding mindfulness among individuals and healthcare experts, presence of an enormous pool of undiscovered patients, quick urbanisation, and expanding government support for healthcare.

The rising instances of cachexia and developments in modern treatment systems are the key industry trends propelling the market's growth.

The major regions in the industry are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.

On the basis of therapeutics, the market is divided into progestogens, corticosteroids, and combination therapy, among others.

Based on mechanism of action, the market is divided into appetite stimulators and weight loss stabilisers.

The several distribution channels include hospital pharmacy, retail pharmacy, and online pharmacy.

The major players in the industry are Merck & Co., Inc., Aphios Corporation, Helsinn Healthcare SA, AVEO Pharmaceuticals, Inc., Ono Pharmaceutical Co., Ltd., and Pfizer Inc., among others.

Purchase Full Report

Mini Report

$ 3499     $2999
  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

$ 5999     $5499
  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update
most popular

Five User License

$ 8299     $7499
  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

$ 10499     $9499
  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Any Question? Speak With An Analyst

Contact Analyst

View A Sample

Request Sample

Did You Miss Anything, Ask Now

Request Customisation
Why Expert Market Research?

Right People

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

Right Methodology

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

Right Price

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

Right Support

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

NEWSLETTER